Cargando…

Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis

BACKGROUND: Testosterone deficiency is common in chronic obstructive pulmonary disease (COPD) patients. There has been a growing interest in the potential use of anabolic-androgenic steroids (AASs) in patients with COPD recently. However, whether AASs could improve their clinical outcomes remains un...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yahui, Huang, Chunrong, Du, Juan, Lan, Gelei, Du, Xueqing, Sun, Yidan, Shi, Guochao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485876/
https://www.ncbi.nlm.nih.gov/pubmed/36148458
http://dx.doi.org/10.3389/fmed.2022.915159
_version_ 1784792155702689792
author Liu, Yahui
Huang, Chunrong
Du, Juan
Lan, Gelei
Du, Xueqing
Sun, Yidan
Shi, Guochao
author_facet Liu, Yahui
Huang, Chunrong
Du, Juan
Lan, Gelei
Du, Xueqing
Sun, Yidan
Shi, Guochao
author_sort Liu, Yahui
collection PubMed
description BACKGROUND: Testosterone deficiency is common in chronic obstructive pulmonary disease (COPD) patients. There has been a growing interest in the potential use of anabolic-androgenic steroids (AASs) in patients with COPD recently. However, whether AASs could improve their clinical outcomes remains unknown. METHODS: In order to explore the efficacy of AASs in patients with COPD, systematic search of MEDLINE, Embase, the Cochrane Library and ClinicalTrials.gov for randomized controlled trials (RCTs) of AASs for COPD published before March 17, 2022 was performed. RESULTS: Data were extracted from 8 articles involving 520 participants. The median number of participants per study was 39.5 and the mean follow up was 14.2 weeks. As compared to the control group, AASs therapy could significantly improve body weight (weighted mean difference (WMD), 1.38 kg; 95% CI, 0.79 to 1.97 kg), fat-free mass (WMD, 1.56 kg; 95% CI, 0.94 to 2.18 kg) and peak workload (WMD, 6.89W; 95% CI, 3.97 to 9.81W) of COPD patients, but no improvements in spirometry indicators and six-minute walking distances (WMD, 16.88 m; 95%, −3.27 to 37.04 m). Based on the available research data, it is uncertain whether AASs treatment could improve the quality of life of COPD patients. CONCLUSIONS: Limited published evidence indicates that AASs therapy provides clinical benefits in patients with COPD. However, longer and larger studies are needed to better clarify the efficacy of AASs and draw final conclusions.
format Online
Article
Text
id pubmed-9485876
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94858762022-09-21 Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis Liu, Yahui Huang, Chunrong Du, Juan Lan, Gelei Du, Xueqing Sun, Yidan Shi, Guochao Front Med (Lausanne) Medicine BACKGROUND: Testosterone deficiency is common in chronic obstructive pulmonary disease (COPD) patients. There has been a growing interest in the potential use of anabolic-androgenic steroids (AASs) in patients with COPD recently. However, whether AASs could improve their clinical outcomes remains unknown. METHODS: In order to explore the efficacy of AASs in patients with COPD, systematic search of MEDLINE, Embase, the Cochrane Library and ClinicalTrials.gov for randomized controlled trials (RCTs) of AASs for COPD published before March 17, 2022 was performed. RESULTS: Data were extracted from 8 articles involving 520 participants. The median number of participants per study was 39.5 and the mean follow up was 14.2 weeks. As compared to the control group, AASs therapy could significantly improve body weight (weighted mean difference (WMD), 1.38 kg; 95% CI, 0.79 to 1.97 kg), fat-free mass (WMD, 1.56 kg; 95% CI, 0.94 to 2.18 kg) and peak workload (WMD, 6.89W; 95% CI, 3.97 to 9.81W) of COPD patients, but no improvements in spirometry indicators and six-minute walking distances (WMD, 16.88 m; 95%, −3.27 to 37.04 m). Based on the available research data, it is uncertain whether AASs treatment could improve the quality of life of COPD patients. CONCLUSIONS: Limited published evidence indicates that AASs therapy provides clinical benefits in patients with COPD. However, longer and larger studies are needed to better clarify the efficacy of AASs and draw final conclusions. Frontiers Media S.A. 2022-09-06 /pmc/articles/PMC9485876/ /pubmed/36148458 http://dx.doi.org/10.3389/fmed.2022.915159 Text en Copyright © 2022 Liu, Huang, Du, Lan, Du, Sun and Shi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Liu, Yahui
Huang, Chunrong
Du, Juan
Lan, Gelei
Du, Xueqing
Sun, Yidan
Shi, Guochao
Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
title Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
title_full Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
title_fullStr Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
title_full_unstemmed Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
title_short Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
title_sort anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485876/
https://www.ncbi.nlm.nih.gov/pubmed/36148458
http://dx.doi.org/10.3389/fmed.2022.915159
work_keys_str_mv AT liuyahui anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis
AT huangchunrong anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis
AT dujuan anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis
AT langelei anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis
AT duxueqing anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis
AT sunyidan anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis
AT shiguochao anabolicandrogenicsteroidsforpatientswithchronicobstructivepulmonarydiseaseasystematicreviewandmetaanalysis